Angiotech Pharmaceuticals (ANP.TO) Buy, Sell…

Angiotech Pharmaceuticals (ANP.TO)

0.00

-0.00 (0.00%)

2 watching

DON'T BUY

What hurts them was they levered up for an acquisition using debt at the wrong time and have never been able to get out from under that cloud of debt and he doesn't think they will.

Wealthica Track your Stocks in your Watch List

BUY ON WEAKNESS

(Market Call Minute.) A lot of biotech stocks have done well. Would buy on a pullback.

DON'T BUY

Had 2 approvals, May 27 and June 8. This is on his Watch list but was far more interesting before May 27 so it now holds no interest for him. Might be okay for momentum players.

COMMENT

The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.

HOLD

Have had serious problems with their stents. The whole area is having issues. Excellent management. They have big pipeline and the technology is still excellent.

SELL

The whole market is going up, and this one is going down. Let someone else own it.

SELL

A one trick pony with its coated stent. There is lots of controversy on drug coated stents.

DON'T BUY

They're very focused on one part of the business, which is stents. There is a lot of competition in this sector. Revenue projections have been dropping.

Wealthica Track your Stocks in your Watch List

COMMENT

Makes drug alluding stents. Its penetration rate in the US was 75% but has dropped to 65%. Will be launching in Japan in the fall. Have a lot of debt on the balance sheet and are in the process of selling assets.

BUY

The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.

DON'T BUY

A “ one trick pony”. There are now lots of questions to the effectiveness of drug-coated stents.

DON'T BUY

Not time to buy this one yet. They have the stent problem and the adoption problem. Lowering their earnings forecasts. Potential recovery, but wait for the recovery.

DON'T BUY

Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.

DON'T BUY

If it breaks $7.35, it is going to go lower. His model price is hugely coming down. In September it was $16 and now it is $10.73, which is a positive differential, but earnings are dropping.

DON'T BUY

Guidance for this year was quite poor. Their stent business is not going to be as robust. Company needs to diversify their asset base and have been slow to do that.

Showing 1 to 15 of 140 entries

Angiotech Pharmaceuticals (ANP.TO) Frequently Asked Questions

What is Angiotech Pharmaceuticals stock symbol?

Angiotech Pharmaceuticals is a OTC stock, trading under the symbol ANP.TO (previously ANP-T on Stockchase) on the undefined (undefined). It is usually referred to as or ANP.TO

Is Angiotech Pharmaceuticals a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on ANP.TO (previously ANP-T on Stockchase) on Stockchase. Read the latest expert commentary for Angiotech Pharmaceuticals.

Is Angiotech Pharmaceuticals a good investment or a top pick?

Angiotech Pharmaceuticals was recommended as a Top Pick by Robert Floyd on 2007-02-13. Read the latest stock experts ratings for Angiotech Pharmaceuticals.

Why is Angiotech Pharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Angiotech Pharmaceuticals.

Is Angiotech Pharmaceuticals worth watching?

Angiotech Pharmaceuticals is covered by Stockchase experts and is worth watching.

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Angiotech Pharmaceuticals (ANP.TO)